Tiziana completes Foralumab Phase 2a enrollment

Tiziana Life Sciences has announced the completion of patient enrollment in its randomized, double-blind, placebo-controlled Phase 2a clinical trial, INFORM-MS (NCT06292923), for intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The trial enrolled 48 patients across multiple leading U.S. sites, who will receive one of two doses of intranasal foralumab or a placebo over a 12-week period. Assessments include PET imaging, MRI, clinical evaluations, and biomarkers. Following the blinded phase, all participants will have the opportunity to enter a six-month open-label extension phase to assess long-term safety and sustained benefit. Topline data is anticipated in late Q3 2026 and will be presented at the 10th joint ACTRIMS and ECTRIMS meeting in Toronto, Canada in October 2026. Ivor Elrifi, CEO, and Gabriele Cerrone, Executive Chairman and Founder of Tiziana Life Sciences, both highlighted the significance of this milestone for the company and for patients with na-SPMS, emphasizing the potential of intranasal foralumab as a novel, non-invasive treatment.